Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Rezvilutamide in Triple Negative Breast Cancer: NCT05928780 Clinical Landscape Report 2026
16 October 2026
NCT05928780 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
FT-596 in Mantle-Cell Lymphoma: NCT05934097 Clinical Landscape Report 2026
16 October 2026
NCT05934097 clinical landscape for Mantle-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Doxorubicin Hydrochloride liposomal in Diffuse Large B-Cell Lymphoma: NCT05933967 Clinical Landscape Report 2026
16 October 2026
NCT05933967 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Imdatifan in Metastatic Renal Cell Carcinoma: NCT05935748 Clinical Landscape Report 2026
16 October 2026
NCT05935748 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Olaparib in Pancreatic adenocarcinoma: NCT05933265 Clinical Landscape Report 2026
16 October 2026
NCT05933265 clinical landscape for Pancreatic adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tazemetostat Hydrobromide in Mantle-Cell Lymphoma: NCT05934838 Clinical Landscape Report 2026
16 October 2026
NCT05934838 clinical landscape for Mantle-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Axicabtagene Ciloleucel in T-cell/histiocyte rich large B-cell lymphoma: NCT05934448 Clinical Landscape Report 2026
16 October 2026
NCT05934448 clinical landscape for T-cell/histiocyte rich large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and developmen…
9 min read
CV09050101 mRNA vaccine(CureVac) in Astrocytoma: NCT05938387 Clinical Landscape Report 2026
16 October 2026
NCT05938387 clinical landscape for Astrocytoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Polatuzumab Vedotin-Piiq in Diffuse Large B-Cell Lymphoma: NCT05940051 Clinical Landscape Report 2026
16 October 2026
NCT05940051 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
UCL-70802 in Hodgkin's Lymphoma: NCT05948033 Clinical Landscape Report 2026
16 October 2026
NCT05948033 clinical landscape for Hodgkin's Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Polatuzumab Vedotin-Piiq in Diffuse Large B-Cell Lymphoma: NCT05940064 Clinical Landscape Report 2026
16 October 2026
NCT05940064 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
HTL-0039732 in MSS/pMMR/MSI-L Colorectal Carcinoma: NCT05944237 Clinical Landscape Report 2026
16 October 2026
NCT05944237 clinical landscape for MSS/pMMR/MSI-L Colorectal Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white s…